9
Participants
Start Date
June 15, 2024
Primary Completion Date
June 15, 2025
Study Completion Date
June 15, 2026
IM83 CAR-T Cells
IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
Guangdong Provincial People's Hospital, Guangdong
Guangdong Provincial People's Hospital
OTHER
Beijing Immunochina Medical Science & Technology Co., Ltd.
INDUSTRY